Builders FirstSource press release (BLDR): Q2 GAAP EPS of -$0.04 misses by $0.79. - Revenue of $3.86B (-8.1% Y/Y) misses by $60M. - Net sales were $3.9 billion, a decrease of 8.8%, primarily due to a lower housing starts environment and related headwinds. The decline refle
Colliers International press release (CIGI): Q2 Non-GAAP EPS of $1.83 beats by $0.02. - Revenue of $1.57B (+16.3% Y/Y) beats by $60M. - 2026 OutlookThe Company reaffirmed its outlook for 2026, which includes the impact of Ayesa. On a consolidated basis, the Company expects
The footwear company raised its FY2026 revenue outlook after Q2 results exceeded analyst expectations. Steven Madden reported Q2 non-GAAP EPS of $0.44, beating estimates by $0.11, as revenue rose 19.1% year-over-year to $665.9M. The result surpassed revenue expectations by
Martin Marietta Materials reports $5.00 EPS and $1.95B revenue for Q2, exceeding expectations and raising full-year guidance. Martin Marietta Materials posted Q2 non-GAAP earnings per share of $5.00, surpassing estimates by $0.24. Revenue reached $1.95 billion, a 21.1% yea
Affiliated Managers Group reports mixed Q2 results with earnings beating expectations but revenue missing estimates by $97.74M. Affiliated Managers Group posted Q2 non-GAAP earnings per share of $8.29, exceeding estimates by $0.37. Revenue reached $493.2M, flat year-over-y
Madrigal Pharmaceuticals reports a narrower-than-expected Q2 loss and revenue growth of 71.2% year-over-year. Madrigal Pharmaceuticals posted a Q2 GAAP loss per share of $1.99, beating estimates by $0.65. Revenue reached $364.3 million, up 71.2% from the same period last y
Donnelley Financial Solutions reports mixed Q2 results with EPS below expectations but revenue exceeding forecasts by $2.8M. Donnelley Financial Solutions posted Q2 GAAP earnings per share of $1.44, missing estimates by $0.03. Revenue reached $224.2 million, a 2.8% year-ov
The company reported a $0.53 non-GAAP EPS, exceeding expectations by $0.17 as revenue grew 9.8% year-over-year. Myers reported second-quarter non-GAAP earnings per share of $0.53, surpassing estimates by $0.17. Revenue reached $179.2 million, up 9.8% from the same period l
Regeneron's Q2 2026 results surpassed analyst expectations, fueled by strong demand for its high-dose Eylea eye therapy. Regeneron Pharmaceuticals (REGN) saw its shares rise in premarket trading after reporting Q2 2026 earnings that exceeded Wall Street estimates. The beat
SXC reports $475.3M revenue and $69.6M adjusted EBITDA, raising full-year 2026 guidance to $250M-$265M. SunCoke Energy posted second-quarter GAAP earnings per share of $0.15, exceeding estimates by $0.08, as revenue rose 9.5% year-over-year to $475.3M. The result surpassed
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.